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Summary
In patients with end-stage heart failure refractory to 
medical and cardiac resynchronisation therapy, heart 
transplantation is recognised as the treatment of 
choice. As compared to medical therapy, heart trans-
plantation is considered to be associated with a surviv-
al benefit, to enhance functional capacity and improve 
quality of life, provided that patients are properly 
selected in accordance with guidelines. However, a pow-
erful trial to compare heart transplantation with 
conventional management is still lacking and is un-
likely to be performed. Individually tailored anti-rejec-
tion regimens, based on the currently used immu- 
nosuppressive agents, have produced an excellent 
survival rate following heart transplantation. Unlike 
the increase in survival in the early phase after trans-
plantation, the attrition rate over the long term has re-
mained similar in recent decades, largely because of 
associated complications such as chronic allograft 
vasculopathy and malignancy, the incidence of which 
could not be markedly reduced. Since the number of 
heart transplantations is limited due to the shortage of 
donor organs, and since, in parallel, the number of 
patients with end-stage heart failure is constantly 
increasing, mechanical circulatory support is gaining 
in importance. The pulsatile devices originally used 
were associated with a high frequency of adverse 
events such as bleeding and thromboembolic events, 
noisiness and patient discomfort, which prevented 
widespread application. The introduction of continu-
ous-flow pumps which are silent and comfortable, and 
cause fewer side effects, has revolutionised mechanical 
circulatory support. Since survival on such devices has 
significantly improved as compared to the previous 
era, implant rates have dramati-
cally increased, particularly as an 
alternative to transplantation. In 
carefully selected patients the out-
come of destination therapy ap-
proaches survival rates close to 
those after heart transplantation. 
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Introduction
Heart failure is a major cause of morbidity and mortal-
ity in the population of the western world, with signifi-
cant societal implications. The direct and indirect cost 
of heart failure in the US for the year 2010 was esti-
mated at $ 39.2 billion [1, 2]. According to AHA statis-
tics for 2010 the prevalence of heart failure in the US 
is 5,800,000, nearly half of these patients (48%) pre-
senting reduced left ventricular function (LVEF <40%). 
30% of patients are in NYHA functional class III or 
higher (class III 25%, class IV 5%) [2]. In the United 
States the incidence of heart failure approaches 10 per 
1,000 people after the age of 65. The 1-year mortality 
for heart failure in this population is as high as 20%. At 
age 40 the lifetime risk of developing heart failure is 
1 in 5 [1]. Since life expectancy is steadily increasing, 
the heart failure population will grow further. Medical 
management of heart failure has substantially im-
proved in recent decades. By introducing angiotensin-
converting enzyme inhibitors and angiotensin-receptor 
antagonists, beta-blockers, aldosterone receptor inhib-
itors and hydralazine/isosorbide dinitrate as main pil-
lars of drug therapy, mortality in patients with heart 
failure and reduced left ventricular function has been 
significantly lowered. The concept of implanting ICDs 
in this patient population was similarly important in 
this context (for references see Fonarow et al. [2]). In 
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sporine had triggered the breakthrough of heart trans-
plantation in the 1980s, the development of tacrolimus, 
another calcineurin inhibitor (CNI), opened up the pos-
sibility of further refining immunosuppression. Ad-
ministration of tacrolimus could be shown to reduce 
the frequency of acute rejection episodes and the inci-
dence of chronic allograft vasculopathy [10]. Also, 
chronic renal disease developed less frequently under 
immunosuppression based on tacrolimus as compared 
to cyclosporine [11]. As a result, tacrolimus is currently 
more widely used as part of maintenance immunosup-
pression. Within the last decade the percentage of all 
patients reported to the ISHLT registry who receive 
tacrolimus at one year after heart transplantation in-
creased from 23% in 2000 to 73% in 2010, while the 
number of patients receiving cyclosporine fell from 
75% to 18% in the same period [9]. 
The second component of immunosuppressive 
therapy: from azathioprine to mycophenolate 
mofetil and mTOR inhibitors
Whereas in the early period of heart transplantation 
azathioprine (AZA) served as the second pillar of the 
immunosuppressive regimen, it has been replaced in 
most centres by mycophenolate mofetil (MMF), which 
was introduced in 1991 [9]. Mycophenolate mofetil has 
been shown to improve survival after heart transplan-
tation as compared to AZA, and to be superior to AZA 
in preventing acute rejection episodes and the develop-
ment of chronic allograft vasculopathy and malignan-
cies [12–14]. However, MMF seems to be associated 
with a higher rate of viral infections [12, 13]. More re-
cently, mammalian target of rapamycin (mTOR) inhib-
itors, also called proliferation signal inhibitors (PSI), 
such as sirolimus and everolimus, have aroused the in-
terest of transplant physicians for use as an immuno-
suppressive agent. They show synergy with the CNIs 
in their anti-rejection potential and, therefore, allow 
reduction of CNI drug doses without compromising 
efficacy, thus lowering nephrotoxicity associated with 
the administration of both drugs [15, 16]. In combina-
tion with cyclosporine or tacrolimus, mTOR inhibitors 
achieve rejection rates which are equivalent or supe-
rior to those seen in mycophenolate mofetil combina-
tions [15]. However, their profile of adverse effects has 
prevented them from being widely used in transplanta-
tion. Currently they are a component of maintenance 
immunosuppression in only 8% of patients at one year 
after heart transplantation [9]. Side effects include 
hyperlipidaemia, wound healing complications, pro-
teinuria and the increase in CNI-induced nephrotoxic-
ity, although they do not present inherent nephrotoxic-
ity. However, due to their antiproliferative effects they 
may bestow particular benefit on heart transplant 
recipients with chronic allograft vasculopathy and 
malignancies, or those at high risk for malignancies 
[15–17]. 
addition, cardiac resynchronisation therapy has been 
shown to be beneficial in selected patients with ad-
vanced as well as mild-to-moderate heart failure [3, 4]. 
In severely advanced heart failure heart transplanta-
tion is still believed to be the gold standard of treat-
ment, although controlled trials have never been per-
formed [5, 6]. The concept of mechanical circulatory 
support was initially introduced to bridge to heart 
transplantation in the most severely ill patients who 
would otherwise not survive the time on the waiting 
list. Due to increasing mismatch between the number 
of patients in need of heart transplantation and the 
pool of suitable donors, mechanical circulatory support 
increasingly emerges as an alternative to heart trans-
plantation, particularly since technical progress has 
made the devices more durable, reliable and comforta-
ble. Against this background the indications and 
results of heart transplantation and mechanical circu-
latory support will be highlighted.
Heart transplantation
In patients with severely advanced heart failure, heart 
transplantation is generally considered to increase 
survival and improve quality of life as compared to con-
ventional medical treatment, given that the patients 
are properly selected [7]. In 2006, the International 
Society for Heart and Lung Transplantation (ISHLT) 
issued distinct listing criteria to provide clear guid-
ance to transplant centres for assessment of cardiac 
function and comorbidities in potentially transplant-
eligible patients [6]. Adequate selection of transplant 
candidates is particularly important, since heart 
transplantation may be associated with a survival ben-
efit only in patients with a predicted high risk of dying 
on the waiting list, whereas patients with a predict- 
ed low or medium risk have no reduction in mortality 
risk associated with transplantation, as was shown in 
a prospective observational study in Germany in 1997 
(COCPIT) [8]. However, a randomised multicentre 
study to compare outcome following heart transplanta-
tion versus optimal medical management in patients 
with end-stage heart failure has not as yet been per-
formed. 
Introduction of cyclosporine: the success story 
of heart transplantation begins
Survival following heart transplantation has continu-
ously improved in recent decades. This is mainly due to 
a reduction in early mortality within the first year af-
ter transplantation. Currently, the 1-year post-trans-
plant survival of all patients reported to the registry of 
the International Society for Heart and Lung Trans-
plantation (ISHLT) is approx. 84% [9]. Improvement of 
peri-operative management and, in particular, ad-
vances in immunosuppressive therapy have contrib-
uted to this success. After the introduction of cyclo-
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Induction therapy – to do it or not to do it?
Induction therapy has always been controversial in 
heart transplantation. The rationale for its use is pre-
vention of early acute rejection. This may allow reduc-
tion of maintenance immunosuppression and have a 
beneficial effect on the development of chronic allograft 
vasculopathy. It is used in 52% of heart transplant pa-
tients worldwide and is more popular in Europe (76% 
of patients) than in the US (51% of patients) [9]. Origi-
nally, polyclonal anti-lymphocyte globulin (ALG) and 
anti-thymocyte globulin (ATG) were used for induction 
therapy. With the introduction of monoclonal interleu-
kin-2 receptor (IL-2R) antagonists, the use of ALG and 
ATG has declined to 20% of patients, while the use of 
IL-2R antagonists has increased to 30% of patients. 
OKT3, a murine monoclonal antibody against the CD3 
antigen on T-cells, has lost its relevance in induction 
therapy, and alemtuzumab, a new, humanised mono-
clonal antibody against the CD52 antigen on mature 
lymphocytes, currently accounts for induction therapy 
in some 3% of patients [9]. However, current data do 
not allow a firm conclusion on the benefit of induction 
therapy. The advantage over an immunosuppressive 
protocol without induction is not clear [9, 19]. Data 
from the 2011 ISHLT registry show no survival benefit 
in patients who received induction therapy as com-
pared to those without induction [9]. Randomised trials 
with induction therapy are lacking [19]. No recent ran-
domised trials comparing ATG with no induction exist. 
Trials comparing IL-2R antagonists with no induction 
have shown contradictory results [19, 20]. Alemtu-
zumab was analysed against no induction in a large 
retrospective study showing a significant reduction 
in rejection episodes. However, survival was lower in 
the alemtuzumab group [21]. Some patient groups may 
particularly benefit from induction therapy. These are 
patients sensitised with circulating preformed antibod-
ies who are at high risk for acute rejection episodes, 
and patients with severe preoperative and periopera-
tive renal dysfunction in whom induction therapy al-
Steroids – the first immunosuppressive drug:  
are they still necessary?
Steroids have been a fundamental element in immuno-
suppression since the beginning of transplantation. 
Because of their numerous side effects, attempts have 
been made in recent years to withdraw steroids from 
the immunosuppressive protocol after varying time 
intervals following heart transplantation, most fre-
quently 6–12 months after transplantation. As yet 
there is no clear evidence in the literature concerning 
the potential risks and benefits of steroid withdrawal. 
In a meta-analysis some positive effects on cardiovas-
cular risk factors were identified, whereas a trend to-
wards an increased risk of acute rejection was seen al-
though with no measurable effect on graft or patient 
survival. The lack of robust evidence requires larger 
scale randomised controlled trials to fully ascertain the 
risk/benefit ratio of steroid withdrawal [18]. Currently 
some 80% of heart transplant recipients remain on 
steroids at one year and some 50% at five years follow-
ing transplantation [9]. 
Figure 1
Survival after heart transplantation: Worldwide and Zurich.
Zurich = Survival of patients transplanted from 1985 to 2011;  
ISHLT (International Society for Heart and Lung Transplantation) =  
Survival of patients transplanted from 1982 to 2010 [9].
Figure 2
Heart transplant waiting list and heart transplants in the Eurotransplant region (source: Eurotransplant Foundation, Leiden, NL [22]).
A Heart waiting list, number of patients at year end, by urgency.
B Number of heart transplants, by recipient urgency at transplant.
A B
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performed within the same period stayed the same 
(fig. 2) [22]. The same trend is seen in Switzerland 
(fig. 3) [23]. As a consequence, the number of highly ur-
gent transplantations in ET has increased from 50% to 
70% of all transplantations in the same time interval 
[22]. Patients who are listed electively on the waiting 
list have a lesser chance of receiving a donor heart. In 
some countries this has already led to the paradoxical 
situation that outcomes after transplantation deterio-
rate due to negative (high risk) patient selection. Be-
cause of the gap between demand and supply of donor 
hearts, the number of patients who have to be bridged 
to transplantation with a ventricular assist device 
(VAD) has increased from 18% in the year 2000 to 32% 
in 2009 [9]. With the advent of newer-generation de-
vices, so-called continuous-flow devices, which are sig-
nificantly reduced in size as compared to first genera-
tion pulsatile devices, survival of patients bridged to 
transplantation has markedly improved and reaches 
post-transplant survival rates similar to patients who 
are transplanted without the need for mechanical sup-
port [9]. Technical advances in the field of ventricular 
assist devices and the resultant success of mechanical 
circulatory support has led to a dramatic increase in 
VAD implantations over the last five years [24]. Since 
heart transplantation cannot cover the demand for 
end-stage heart failure therapy, and its associated 
long-term complications are still not controlled, me-
chanical circulatory support is increasingly considered 
as an alternative to heart transplantation.
Mechanical circulatory support –  
an alternative to transplantation?
Introduction of continuous-flow devices:  
the success story of mechanical circulatory 
support begins
Mechanical circulatory support was originally imple-
mented to bridge patients to heart transplantation who 
would otherwise not survive the time on the waiting 
list. In the mid-1980s, when VADs found their way into 
clinical use, they consisted of a large pulsatile pump 
weighing ca. 1 kg which was implanted intracorpore-
ally into the abdominal wall, such as the Novacor N100 
(originally Baxter, later World Heart Inc., Ottawa, 
Canada) and HeartMate
®
 I (originally Thermo Cardio-
systems, Inc., Woburn, MA, USA; currently: Thoratec 
Inc., Pleasanton, CA, USA) [25, 26]. Alternatively, the 
pumps were located paracorporeally outside the body, 
like the Thoratec VAD (Thoratec Inc., Pleasanton, CA, 
USA) and the Berlin Heart Excor (Berlin Heart GmbH, 
Berlin, Germany) [27, 28]. Although, with increasing 
experience, survival on the device reached rates of 
approximately 60–70%, adverse events including 
thrombosis and embolism, bleeding, infection, and 
mechanical failure, as well as patient discomfort due to 
the size and noisiness of the pumps, precluded more ex-
lows a delay in onset of treatment with nephrotoxic 
CNI without running a higher risk of acute rejection 
[19]. 
Excellent long-term results contrast  
with unsolved late complications 
Long-term results following heart transplantation are 
excellent, particularly if they are compared with medi-
cal management of end-stage heart failure. According 
to the international registry, ca. 53% of patients are 
still alive ten years after transplantation, and ca. 26% 
after 20 years [9]. At Zurich University Hopital 10-year 
survival compares favourably with the ISHLT registry 
data with 65% 10-year survival and 50% survival at 20 
years (fig. 1). In contrast to the improvement in early 
survival after heart transplantation, the attrition rate 
in the long term has remained similar over the years. 
Independently of the era, some 3–4% of patients die per 
year [9]. This might be attributable to the long-term 
complications following heart transplantation, such as 
chronic allograft vasculopathy and malignancy, which 
account for ca. 35% of all deaths 10 to 15 years follow-
ing heart transplantation [9]. Despite improvement in 
posttransplant management, over the last two dec-
ades, it has only been possible to reduce the incidence 
of chronic allograft vasculopathy and malignancy at 
8 years after transplantation from 47% to 45% and 
from 28% to 23%, respectively.
The problem: not enough donor hearts for the 
increasing number of transplant candidates
While the number of patients in need of a heart trans-
plant is steadily increasing, the number of suitable do-
nors cannot keep up with this demand. The total count 
of heart transplantations worldwide has remained 
more or less unchanged since 2002 at some 3,700 per 
year [9]. In the Eurotransplant (ET) region, the num-
ber of patients on the waiting list has doubled from 
2003 to 2011, but the number of heart transplantations 
Figure 3
Heart transplant waiting list and heart transplants in Switzerland (source: Swiss-
transplant, Bern, CH [23]).
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transplantation were randomised to left ventricular 
assist device (LVAD) therapy versus optimal medical 
management (OMM) [34]. Patients on mechanical sup-
port had a significant survival benefit over medically 
treated patients. After one year, 52% of patients in the 
LVAD group were alive, as opposed to 25% in the 
OMM group (p = 0.002). At two years, survival was still 
higher in the device group (23%) than in the OMM 
group (8%), but did not reach statistical significance 
(p = 0.09). Adverse events such as bleeding, neurologi-
cal dysfunction and infection were significantly more 
frequent in the device group, whereas quality of life 
was better in the device group than in the medical 
group. In the REMATCH trial the HeartMate
®
 I was 
used for LVAD therapy. As outlined above, this was a 
first generation device of large size and associated with 
clinically significant adverse events including pocket 
and driveline infection and limited mechanical reliabil-
ity and durability [35]. Since the introduction of contin-
uous-flow devices, pumps have become available which 
are smaller, quieter and more durable than pulsatile 
devices, making them potentially more suitable for 
long-term support. This prompted investigators to 
compare the performance and adverse events of first 
generation pulsatile devices with second generation 
continuous-flow pumps. In a landmark trial, patients 
with end-stage heart failure NYHA class III b or IV, 
who were ineligible for transplantation, were ran-
domised to undergo implantation of a continuous-flow 
pump (HeartMate
®
 II) or pulsatile-flow device (Heart-
Mate
®
 I) [36]. Actuarial survival was significantly bet-
ter for patients with a continuous-flow device as com-
pared to those with a pulsatile-flow pump. After one 
and two years, 68% and 58% of patients respectively 
with a continuous-flow pump were alive, but only 55% 
and 24% of patients, respectively, with a pulsatile 
pump. In addition, adverse events such as device-re-
lated and non-related infections as well as right heart, 
respiratory and renal failure were less frequent in pa-
tensive use other than in the most severely ill patients 
with end-stage heart failure. The introduction of con-
tinuous-flow pumps in 1998 revolutionised mechanical 
circulatory support. Due to the new principle of rotat-
ing pumps, the size of the housing could be markedly 
reduced. Implantation became much easier, and pa-
tient comfort increased significantly. However, experi-
ence with the first such pump, the axial-flow MicroMed 
DeBakey VAD (MicroMed Cardiovascular, Inc., Hous-
ton, TX, USA), did not live up to expectations. The 
survival rate on the pump of ca. 55% could not compare 
with that on pulsatile devices [29]. Pump thrombus 
formation turned out to be a major problem, causing 
thromboembolism and irreversible pump stop which 
certainly contributed to the disappointing results. 
With further advances in axial-flow technology, second 
generation pumps such as the Jarvik 2000 (Jarvik 
Heart, Inc., New York, NY, USA), the Berlin Heart 
Incor (Berlin Heart GmbH, Berlin, Germany) and the 
HeartMate
®
 II (Thoratec Inc., Pleasanton, CA, USA) 
became available. Survival on the pump or to trans-
plantation improved, and adverse effects were reduced 
[30–32]. The introduction of centrifugal pumps as the 
third generation of assist devices may further improve 
outcomes (fig. 4) [33]. 
Improved results with continuous-flow devices 
pave the way for destination therapy
Due to the persistent shortage of donor hearts and the 
increasing number of patients with advanced heart 
failure, mechanical circulatory support is under in-
creasing consideration as an alternative treatment 
rather than a bridge to heart transplantation, particu-
larly in the light of the significant technical improve-
ments in the devices. A first attempt to compare VAD 
therapy with conservative medical treatment in end-
stage heart failure patients was made at the turn of the 
millennium. In the revolutionary REMATCH trial, pa- 
tients in NYHA IV heart failure not eligible for heart 
Figure 4
The third-generation 
centrifugal pump Heart-
Ware
®
 (by courtesy of 
HeartWare International, 
Inc., Framingham, MA, USA). 
A  The HeartWare
®
  
LVAD in situ.
B, C  The size of the 
HeartWare
®
 in 
comparison with a golf 
ball and an adult hand.
A
B
C
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agency Registry For Mechanically Assisted Circulatory 
Support (INTERMACS) analyses FDA-approved dura-
ble mechanical circulatory support device implants in 
the United States. Since its launch in June 2006 more 
than 4,500 patients with a primary device implant 
have been entered into the database. The actuarial 
survival among all implants amounts to 78% at one 
year and 68% at two years. The need for BVAD support 
is associated with a marked reduction in survival. In 
the recent period from 2008–2011, overall survival for 
all implants has significantly improved as compared to 
the previous years and currently exceeds 80% (fig. 6). 
This may be explained for the most part by the shift in 
device type away from pulsatile-flow technology to con-
tinuous-flow devices over the last four years. Currently 
more than 99% of all LVAD implants are continuous-
flow pumps (fig. 7). The rise of such pumps is related to 
their excellent success rate. Survival at one and two 
years after implantation is significantly higher with 
continuous-flow devices (82% and 74%, respectively) 
than with pulsatile pumps (61% and 43%, respectively) 
(fig. 8). If outcome on continuous-flow pumps is ana-
lysed by the initial intention-to-treat, the one-year sur- 
vival of patients on destination therapy (78%) comes 
close to that of patients who are bridged to transplant 
(89%) (fig. 9). In the light of such dramatic improve-
ment in survival of patients on modern devices, the 
European Society of Cardiology has upgraded its rec-
ommendation for LVAD implantation in patients with 
end-stage heart failure who are not eligible for heart 
transplantation but expected to survive more than one 
year, from a class IIb to a class IIa recommendation, 
meaning that in those patients LVAD implantation 
should be considered [7].
Identification of risk factors helps in selecting 
patients suitable for destination therapy
To further improve the results of VAD therapy, the in-
fluence of preoperative risk factors needs to be investi-
gated. Thus, the fourth INTERMACS Annual Report 
presented an analysis of risk factors concerning the en-
tire patient population of primary device implants [24]. 
In the first three months after implant, cardiogenic 
shock corresponding with INTERMACS level 1, the 
need for BVAD support, older age, larger BSA, history 
of cardiac surgery (CABG or valve), higher bilirubin 
and higher creatinine were identified as risk factors for 
death in all patients. In the “chronic” phase, between 
one and three years following implantation, the pres-
ence of a pulsatile-flow VAD was the most prominent 
risk factor. Further detailed risk analyses are certainly 
required which examine risk factors in the different 
subgroups of device type (LVAD, BVAD), pump type 
(continuous-flow, pulsatile-flow) and device strategy 
(bridge to transplant, destination therapy). Most re-
cent data indicate that in selected patients without the 
most prominent risk factors, one-year survival on des-
tients with the continuous-flow device. Also, there was 
a significant reduction in the rate of rehospitalisation 
and a significant improvement in device durability in 
the continuous-flow pump group. Quality of life and 
functional capacity improved in both groups. Interest-
ingly, survival of patients on pulsatile pumps in this 
study was similar to the survival of the device patients 
in the REMATCH trial, showing that in the time period 
of eight years since then there has been no potential for 
improvement with pulsatile pumps (fig. 5) [37]. 
The increasing use of ventricular assist devices 
and the continuously improving survival of patients 
with such therapy is reflected in the recently published 
fourth INTERMACS Annual Report [24]. The Inter-
Figure 5
Survival rates in two trials of LVADs as destination therapy (REMATCH trial 2001, 
HeartMate
®
 II destination therapy trial 2009). (From [37]: Fang JC. Rise of the 
machines – left ventricular assist devices as permanent therapy for advanced heart 
failure. N Engl J Med. 2009;361:2282–5. Copyright © 2009 Massachusetts Medical 
Society. Reprinted with permission from the Massachusetts Medical Society.)
Figure 6
Actuarial survival following ventricular assist device implantation, 
stratified by era. (Reprinted from [24]: Kirklin JK, Naftel DC, Kormos  
RL, et al. The Fourth INTERMACS Annual Report: 4,000 implants  
and counting. J Heart Lung Transplant. 2012;31:117–26.  
Copyright © 2012 Elsevier, Oxford, UK, reprinted with permission.)
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tination therapy can compete with one-year survival 
following heart transplantation (approx. 85%) [38].
Technical advances in devices will further  
increase the number of implants
Future trends in this rapidly evolving field focus on 
several different aspects. Miniaturisation of internal 
and external components will allow minimally invasive 
implantation with less surgical trauma, avoidance of 
cardiopulmonary bypass and reduced hospital stay. 
With advances in technology adverse events may be re-
duced, device durability and reliability enhanced, and 
quality of life improved. When transcutaneous energy 
transfer is available devices will be fully implantable, 
with no need for external components and drivelines 
penetrating the skin, hereby reducing device-related 
infection. Some of these developments are already on 
the horizon. They will further revolutionise mechanical 
circulatory support and lead to even wider application 
of mechanical devices.
Conclusion
Heart transplantation has been the gold standard for 
treatment of patients with end-stage heart failure in 
recent decades. Refinement of immunosuppressive 
therapy and posttransplant management have im-
proved its results. However, long-term complications 
Figure 7
Number of LVAD implantations, stratified by 
device type and implant year. (Reprinted from [24]: 
Kirklin JK, Naftel DC, Kormos RL, et al. The Fourth 
INTERMACS Annual Report: 4,000 implants and 
counting. J Heart Lung Transplant. 2012;31:117–
26. Copyright © 2012 Elsevier, Oxford, UK, 
reprinted with permission.)
Figure 8
Actuarial survival following implantation of continuous-flow (CFP) 
versus pulsatile-flow pumps (PFP). (Reprinted from [24]: Kirklin JK, 
Naftel DC, Kormos RL, et al. The Fourth INTERMACS Annual Report: 
4,000 implants and counting. J Heart Lung Transplant. 2012;31:117–
26. Copyright © 2012 Elsevier, Oxford, UK, reprinted with permission.)
Figure 9
Actuarial survival for primary continuous-flow implants, depending on 
the initial device strategy (“intention-to-treat”). (Reprinted from [24]: 
Kirklin JK, Naftel DC, Kormos RL, et al. The Fourth INTERMACS Annual 
Report: 4,000 implants and counting. J Heart Lung Transplant. 
2012;31:117–26. Copyright © 2012 Elsevier, Oxford, UK, reprinted 
with permission.)
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following heart transplantation are still an unsolved 
problem. Due to the continuing shortage of donor 
hearts and the increasing number of patients with end-
stage heart failure who are not eligible for transplanta-
tion, the need for mechanical circulatory support has 
grown. The availability of modern continuous-flow 
pumps has dramatically improved the outcome of this 
therapy. This has led to rapid growth of device implan-
tations in recent years. With future advances in tech-
nology it is foreseeable that mechanical circulatory 
support will further increase its success and may be-
come competitive with heart transplantation.
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